University of Dundee - Confidence in Concept 2014
Lead Research Organisation:
University of Dundee
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The University of Dundee and its Drug Discovery Unit (DDU) is converting world-class discovery research into patient benefit through a portfolio of small molecule translational projects, the Innovative Targets Portfolio (ITP). The ITP, initiated by an MRC-DPFS devolved portfolio and extended with the first two Confidence in Concept awards, is a collaborative activity between the DDU and groups in and outside Dundee who wish to translate their discovery research.
The primary goal of the ITP is to de-risk novel targets and mechanisms to the stage that the BioPharma industry is willing to partner the project for development into marketed therapies to address unmet medical need. The ITP is a dynamic initiative, with projects entering and leaving the portfolio in a continuous rolling process.
Although the ITP is supported by a range of funding streams, these funds are insufficient to meet the demand from multiple potential collaborators, both within Dundee and across the UK, who have identified novel potential drug targets and are seeking to translate their ideas.
A renewed Confidence in Concept award would help maintain the resources available to run multiple hit discovery campaigns and hit series validation projects by the DDU. The aim is to determine the druggability/ligandability of novel targets/mechanisms and to identify high quality hit series, validated in cell-based models. The requested resources will synergise with the ITP team members supported through other funding routes, providing excellent added-value to the Confidence in Concept award.
We believe a portfolio approach is the best way to maximise resource in early stage drug discovery. This approach allows multiple projects to rapidly access an appropriate amount of hit discovery and medicinal chemistry, in a cost-effective way, to assess whether they justify further drug discovery efforts and progression towards in vivo evaluation. This will be achieved using appropriate funding streams e.g. MRC-DPFS/DCS scheme.
The University of Dundee already has the infrastructure and experience required to continue to deliver success under expanded further Confidence in Concept award, including: assay development, hit discovery, medicinal and computational chemistry, and pharmacokinetics.
The primary goal of the ITP is to de-risk novel targets and mechanisms to the stage that the BioPharma industry is willing to partner the project for development into marketed therapies to address unmet medical need. The ITP is a dynamic initiative, with projects entering and leaving the portfolio in a continuous rolling process.
Although the ITP is supported by a range of funding streams, these funds are insufficient to meet the demand from multiple potential collaborators, both within Dundee and across the UK, who have identified novel potential drug targets and are seeking to translate their ideas.
A renewed Confidence in Concept award would help maintain the resources available to run multiple hit discovery campaigns and hit series validation projects by the DDU. The aim is to determine the druggability/ligandability of novel targets/mechanisms and to identify high quality hit series, validated in cell-based models. The requested resources will synergise with the ITP team members supported through other funding routes, providing excellent added-value to the Confidence in Concept award.
We believe a portfolio approach is the best way to maximise resource in early stage drug discovery. This approach allows multiple projects to rapidly access an appropriate amount of hit discovery and medicinal chemistry, in a cost-effective way, to assess whether they justify further drug discovery efforts and progression towards in vivo evaluation. This will be achieved using appropriate funding streams e.g. MRC-DPFS/DCS scheme.
The University of Dundee already has the infrastructure and experience required to continue to deliver success under expanded further Confidence in Concept award, including: assay development, hit discovery, medicinal and computational chemistry, and pharmacokinetics.
People |
ORCID iD |
Michael Ferguson (Principal Investigator) |
Publications

Evans JC
(2021)
Targeting Mycobacterium tuberculosis CoaBC through Chemical Inhibition of 4'-Phosphopantothenoyl-l-cysteine Synthetase (CoaB) Activity.
in ACS infectious diseases

Heap RE
(2017)
Identifying Inhibitors of Inflammation: A Novel High-Throughput MALDI-TOF Screening Assay for Salt-Inducible Kinases (SIKs).
in SLAS discovery : advancing life sciences R & D

Mendes V
(2021)
Inhibiting Mycobacterium tuberculosis CoaBC by targeting an allosteric site.
in Nature communications

Moynié L
(2016)
A Substrate Mimic Allows High-Throughput Assay of the FabA Protein and Consequently the Identification of a Novel Inhibitor of Pseudomonas aeruginosa FabA.
in Journal of molecular biology
Description | European Lead Factory |
Amount | £500,000 (GBP) |
Organisation | European Commission |
Department | Innovative Medicines Initiative (IMI) |
Sector | Public |
Country | Belgium |
Start | 05/2017 |
Description | High growth spinout |
Amount | £131,000 (GBP) |
Organisation | Scottish Enterprise |
Sector | Public |
Country | United Kingdom |
Start | 08/2020 |
End | 03/2021 |
Description | MRC |
Amount | £823,000 (GBP) |
Funding ID | MR/P000509/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start |
Description | project grant |
Amount | £209,048 (GBP) |
Organisation | Versus Arthritis |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2014 |
End | 12/2016 |
Description | project grant |
Amount | £261,067 (GBP) |
Organisation | Arch Therapeutics |
Sector | Private |
Country | United States |
Start | 01/2017 |
End | 12/2019 |
Description | translational medical research fund 2014 |
Amount | £18,500 (GBP) |
Organisation | University of Dundee |
Sector | Academic/University |
Country | United Kingdom |
Start | 03/2014 |
Description | Hit TB TbCoABC sub-project |
Organisation | Foundation for the National Institutes of Health (FNIH) |
Country | United States |
Sector | Charity/Non Profit |
PI Contribution | Data and assays generated by the CiC supported HTS project. The hit Tb grant (our funded resource from the collaboration) we will support 1 FTE years chemistry and computational chemistry plus purchasing of commercial analogues of the hits. |
Collaborator Contribution | Structural biology Tb cell biology and animal model work on selected examples. Fragment screening data and assays. |
Impact | To early to generate defined outputs |
Start Year | 2015 |
Description | Investment Partnership Agreement |
Organisation | Perceptive Bioscience Holdings Ltd |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | The University has signed an Investment Partnership Agreement with Perceptive that will allow the DDU to further translate programmes developed with MRC CiC funding up to preclinical candidates. |
Collaborator Contribution | Perceptive will underwrite the CURE Fund for up to 10 years. |
Impact | The investment sum will be disclosed later in the year. |
Start Year | 2016 |
Company Name | HepaRegeniX GmbH |
Description | HepaRegeniX is a biopharmaceutical company focused on the discovery, development and clinical testing of selective and potent MKK4 inhibitors for liver disease and human tissue regeneration. The company, spun out of the University of Tubingen, was registered in January 2016 and has signed a collaboration with the DDU in Dundee where we have developed an screening assay for MKK4 and completed a diversity screen. The group in Germany was introduced to us through Boehringer Ingelheim Venture Fund who were looking for Dundee input to the technology before they committed to funding a spinout. |
Year Established | 2016 |
Impact | Heparegenix currently only has a handfull of employees but is expected to have 20 by the year end when full funding has been secured. Dundee will be awarded £154,000 to acquire sole ownership of the Dundee MKK4 data. |
Website | http://www.recently-registered.com/www/heparegenix.com |
Company Name | HepaRegeniX GmbH |
Description | HepaRegeniX is a biopharmaceutical company focused on the discovery, development and clinical testing of selective and potent MKK4 inhibitors for liver disease and human tissue regeneration. The company, spun out of the University of Tubingen, was registered in January 2016 and has signed a collaboration with the DDU in Dundee where we have developed an screening assay for MKK4 and completed a diversity screen. The group in Germany was introduced to us through Boehringer Ingelheim Venture Fund who were looking for Dundee input to the technology before they committed to funding a spinout. |
Year Established | 2016 |
Impact | Heparegenix currently only has a handfull of employees but is expected to have 20 by the year end when full funding has been secured. Dundee will be awarded £154,000 to acquire sole ownership of the Dundee MKK4 data. |
Website | http://www.recently-registered.com/www/heparegenix.com |